Pre-market hot trades in US stocks: Nocera up 8.26% in pre-market; Royal Gold down 7.12% in pre-market

Popular Pre-Market Trades in US Stocks Nocera is up 8.26% in pre-market. There has been no significant news recently; trading is active with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news Royal Gold is down 7.12% in pre-market. There has been no significant news recently; trading is active with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news Top Gainers in Pre-Market US Stocks China Natural Resources is up 66.06% in pre-market. Based on recent key news: On March 19, China Natural Resources announced it had signed a non-binding letter of intent with Feishang Group to acquire a majority stake in HooRii Technology. This acquisition marks the company's strategic shift towards physical AI, with an expected transaction amount of $37 million to $40 million, to be paid in cash and stock. This news has significantly boosted the stock price. Source: Company announcement On March 19, trading volume for China Natural Resources surged, exceeding 16.6 million shares, compared to an average daily trading volume of about 42,000 shares over the past three months, indicating strong investor interest in the acquisition plan. Source: Company announcement On March 19, China Natural Resources plans to strengthen its mining operations while transitioning into the AI sector, forming a dual business focus. This move is seen as a potential driver for the company's business growth. Source: Company announcement. The AI industry transition has attracted market attention, leading to active trading. Serina Therapeutics is up 44.53% in pre-market. Based on recent key news: On March 19, Serina Therapeutics announced it had reached an agreement with investors to raise up to $30 million through private financing. This move aims to support its registration trial for Parkinson's disease, driving the stock price up. According to MT Newswires, the financing structure includes potential additional gains from future warrant exercises. On March 19, Serina Therapeutics' stock price rose to $1.64 in after-hours trading, an increase of 28.13%. Company management emphasized that the first patient has been treated, and FDA feedback confirmed a clear regulatory pathway, boosting market confidence. On March 18, Serina Therapeutics announced it entered into a $30 million private financing agreement to advance its registration trial for Parkinson's disease. According to Benzinga Pro data, the stock price fell 4.48% during regular trading hours, but the financing news drove the stock price up in after-hours trading. Recent financing activities in the biotech industry have intensified market volatility. Mobix Labs is up 35.02% in pre-market. Based on recent news, On March 19th, Mobix Labs announced that it was selected by a major arms manufacturer to participate in an early feasibility program focused on smart ammunition technology, aimed at enhancing ammunition's capability against drones. The program is limited to feasibility assessment and does not include production or deployment. This news significantly boosted market confidence, leading to a substantial increase in stock prices. The prospects for smart ammunition technology are promising, and the market response has been positive